Genolution Presents Exosome and Liquid Biopsy Technologies at North American Nephrology Conference
Predicted impact: Low
Conference presentation of technologies; no financial impact disclosed.
Genolution제놀루션
225220 · KOSDAQ · ₩225220 · 제놀루션
₩1,711▲ ₩22 (1.30%)End-of-day · Oct 27, 2026 · End-of-day prices.
Price · 1Y −23.62%
- Market cap
- ₩33B
- Enterprise value
- ₩13B
- P/E
- —
- P/B
- 0.5×
- Dividend yield
- 0.0%
- ROE
- −6.7%
- Net margin
- −46.5%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−25.6% from the high
₩957Today: ₩1,656 – ₩1,724₩2,300
Returns
- 1W+15.6%
- 1M+19.0%
- 3M+32.8%
- 6M−12.3%
- YTD−9.9%
- 1Y−23.6%
- Volume today
- 26,773
- 0.6× the 20-day average
- Traded today
- ₩46M
- Listed shares
- 19,190,021
- EPS (12 months)
- −₩243
- Earnings yield −14.2%
AI researchResearch being writtenOur AI is writing a report on this company from filed data, prices and news. Check back soon.
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 37 of 100 (50 is a normal day for this stock).
- SentimentMixedNews: One neutral conference update with no clear positive or negative news. Community: 0 bullish, 0 bearish posts this week.
- MomentumStrong21% over the last month; the price is above its 20-day average.
- News impactLow3 news items and filings in two weeks; 0 rated high impact, 0 medium.
Signals describe activity, not recommendations. Not financial advice.
Genolution stock overview
Genolution (제놀루션, KRX: 225220) is listed on KOSDAQ, in the Biotech & Pharma sector. The company develops and sells molecular diagnostic products based on genetic material, including nucleic acid extraction reagents and automated nucleic acid extraction instruments made from human-derived samples such as blood, urine and swabs. Its shares closed at ₩1,711 on Oct 27, 2026, up 1.30% on the day, giving it a market value of ₩33B.
Key facts
- Market cap
- ₩33B
- Sector
- Biotech & Pharma
- Latest price change
- +1.30%
- As of
- Oct 27, 2026
- Main business
- The company develops and sells molecular diagnostic products based on genetic material, including nucleic acid extraction reagents and automated nucleic acid extraction instruments made from human-derived samples such as blood, urine and swabs.
Quick answers about Genolution
- What does Genolution do?
- The company develops and sells molecular diagnostic products based on genetic material, including nucleic acid extraction reagents and automated nucleic acid extraction instruments made from human-derived samples such as blood, urine and swabs. It also runs an RNAi-based business that produces and sells double-stranded RNA products and provides shRNA and siRNA synthesis services, mainly to universities, national research institutes and companies in more than ten countries. Domestic sales go through distributors and direct transactions, while overseas sales are handled through overseas distributors and trade shows.
- What is the market cap of Genolution?
- The market capitalisation of Genolution was ₩33B at the close on Oct 27, 2026.
- Who are the largest shareholders of Genolution?
- According to the latest official filings, the largest reported holders are Kim Gi-ok (28.65%, as of Oct 16, 2026); Kim Min-yi (3.80%, as of Oct 16, 2026); KimSangHoon (2.13%, as of Jan 21, 2025).
- When is the next earnings report from Genolution?
- Korean companies rarely announce results dates in advance. Based on when Genolution filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
Company profile
The company develops and sells molecular diagnostic products based on genetic material, including nucleic acid extraction reagents and automated nucleic acid extraction instruments made from human-derived samples such as blood, urine and swabs. It also runs an RNAi-based business that produces and sells double-stranded RNA products and provides shRNA and siRNA synthesis services, mainly to universities, national research institutes and companies in more than ten countries. Domestic sales go through distributors and direct transactions, while overseas sales are handled through overseas distributors and trade shows.
Written by AI from the company's latest annual report.
- Korean name
- 제놀루션
- Sector
- Biotech & Pharma
- Themes
- Biotech (new drugs)
- CEO
- 김기옥, 김민이(공동대표이사)
- Founded
- Feb 2006
- Listed
- Jul 2020
- Listed shares
- 19,190,021
- Fiscal year ends
- Month 12
- Website
- genolution.co.kr
Similar companies
- Samsung Biologics207940 · ₩64T₩1,374,000−5.37%
- Celltrion068270 · ₩44T₩188,600−0.74%
- Alteogen196170 · ₩15T₩218,5000.00%
- Yuhan000100 · ₩5.9T₩80,000−2.08%
- SK biopharmaceuticals326030 · ₩5.9T₩74,900−1.19%
- HLB028300 · ₩5.3T₩39,900+1.66%
- Hanmi Pharm128940 · ₩4.5T₩350,500−0.57%
- SAM Chun Dang Pharm000250 · ₩4.4T₩187,600−0.69%
Recent news
Recent filings
See all- 5%+ holding reportOct 16, 2026
- Insider shareholding reportOct 16, 2026
- Insider shareholding reportOct 2, 2026
- Insider shareholding reportSep 18, 2026
- Insider shareholding reportSep 18, 2026
Titles in Korean until English translations are added.
Also known as: Genolution / 제놀루션 / 225220 / KRX:225220
Source: KRX statistical information